Biogen (NASDAQ:BIIB) Stock Acquired Rep. Maria Elvira Salazar

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Biogen stock on May 12th. The trade occurred in the Representative’s “UBS BROKERAGE ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 5/29/2026.
• Purchased $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 5/21/2026.
• Purchased $15,001 – $50,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
• Purchased $1,001 – $15,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
• Purchased $15,001 – $50,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
• Purchased $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
• Sold $1,001 – $15,000 in shares of Sherwin-Williams (NYSE:SHW) on 5/12/2026.
• Purchased $50,001 – $100,000 in shares of Biogen (NASDAQ:BIIB) on 5/11/2026.
• Sold $1,001 – $15,000 in shares of Whirlpool (NYSE:WHR) on 5/11/2026.
• Purchased $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 5/11/2026.

Biogen Trading Down 2.4%

NASDAQ BIIB opened at $194.24 on Thursday. The firm has a market capitalization of $28.68 billion, a P/E ratio of 20.84 and a beta of 0.20. The business has a fifty day simple moving average of $188.07 and a 200 day simple moving average of $184.03. Biogen Inc. has a 12 month low of $121.05 and a 12 month high of $205.97. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.Biogen’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, analysts predict that Biogen Inc. will post 14.18 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. JPMorgan Chase & Co. increased their price target on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Morgan Stanley increased their price target on Biogen from $200.00 to $206.00 and gave the company an “equal weight” rating in a research report on Thursday, April 30th. Barclays started coverage on Biogen in a research report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 price target for the company. Needham & Company LLC upgraded Biogen from a “hold” rating to a “buy” rating and set a $255.00 price objective for the company in a research note on Monday. Finally, Guggenheim upped their price objective on Biogen from $246.00 to $260.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Biogen currently has an average rating of “Moderate Buy” and a consensus target price of $217.26.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Caprock Group LLC bought a new position in shares of Biogen during the 3rd quarter worth $742,000. Leuthold Group LLC bought a new position in shares of Biogen during the 3rd quarter worth $3,294,000. Generali Investments Management Co LLC grew its stake in shares of Biogen by 408.2% during the 3rd quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock worth $1,397,000 after acquiring an additional 8,008 shares during the period. SG Americas Securities LLC grew its stake in shares of Biogen by 1,793.8% during the 4th quarter. SG Americas Securities LLC now owns 183,829 shares of the biotechnology company’s stock worth $32,352,000 after acquiring an additional 174,122 shares during the period. Finally, TD Asset Management Inc grew its stake in shares of Biogen by 12.7% during the 3rd quarter. TD Asset Management Inc now owns 161,195 shares of the biotechnology company’s stock worth $22,580,000 after acquiring an additional 18,168 shares during the period. Institutional investors own 87.93% of the company’s stock.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Needham upgraded Biogen to Buy and set a $255 price target, citing a stronger outlook for the commercial portfolio and multiple Phase 3 readouts through 2029, including potential upside from Leqembi and recently acquired products. Article Title
• Positive Sentiment: At Biogen’s 2026 annual meeting, shareholders backed the board, auditor, and pay policies, which suggests governance support and no major shareholder revolt. Article Title
• Neutral Sentiment: Commentary comparing Biogen with other biotech stocks says the company has recently outperformed peers and analysts remain reasonably upbeat, reinforcing a stable sentiment backdrop rather than a new catalyst. Article Title
• Negative Sentiment: The Schall Law Firm announced a securities-law investigation into whether Biogen made false or misleading statements or omitted material information, adding headline risk and potential litigation overhang. Article Title
• Negative Sentiment: Pomerantz LLP also launched an investor investigation into Biogen, reinforcing concerns that the stock could face legal scrutiny and additional uncertainty. Article Title

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.